Navigation Links
Gene therapy cures a severe paediatric neurodegenerative disease in animal models
Date:7/2/2013

Sanfilippo Syndrome type A, or Mucopolysaccharidosis type IIIA (MPSIIIA), is a neurodegenerative disease caused by mutations in the gene that encodes the enzyme sulfamidase. Mutations in this gene lead to deficiencies in the production of the enzyme, which is essential for the breakdown of substances known as glycosaminoglicans. If these substances are not broken down, they accumulate in the cells and cause neuroinflammation and organ dysfunction, mainly in the brain, but also in other parts of the body. Children born with this mutation are diagnosed from the age of 4 or 5. They suffer neurodegeneration, causing mental retardation, aggressiveness, hyperactivity, sleep alterations, loss of speech and motor coordination, and they die in adolescence.

A team of researchers headed by the director of the UAB's Centre for Animal Biotechnology and Gene Therapy (CBATEG), Ftima Bosch, has developed a gene therapy treatment that cures this disease in animal models, with pre-clinical studies in mice and dogs. The treatment consists of a single surgical intervention in which an adenoassociated viral vector is injected into the cerebrospinal fluid, the liquid that surrounds the brain and the spinal cord. The virus, which is completely harmless, genetically modifies the cells of the brain and the spinal cord so that they produce sulfamidase, and then spreads to other parts of the body, like the liver, where it continues to induce production of the enzyme.

Once the enzyme's activity is restored, glycosaminoglican levels return to normal for life, their accumulation in cells disappears, along with the neuroinflammation and dysfunctions of the brain and other affected organs, and the animal's behaviour and its life expectancy return to normal. While mice with the disease lived only up to 14 months, those given the treatment survived as long as healthy ones.

This is a joint project between the UAB and the pharmaceutical company Esteve. The study has been published in the online edition of The Journal of Clinical Investigation.


'/>"/>

Contact: Fàtima Bosch
Fatima.bosch@uab.cat
34-935-814-182
Universitat Autonoma de Barcelona
Source:Eurekalert

Related medicine news :

1. Pufferfish neurotoxin may serve as treatment for cancer therapy related pain
2. A circuitous route to therapy resistance
3. Vein Therapy News Magazine Publishes Laser Facelift Article by Dr. Robin Fleck
4. Rural women less likely to get radiation therapy after lumpectomy for breast cancer
5. New understanding of why anti-cancer therapy stops working at a specific stage
6. Past Life Regression Therapy: Valid Treatment or Ridiculous Foo Foo; Researcher and Author Dr. Heather Friedman Rivera on Dr. Carol Francis Radio Talk Show
7. Genetics of cervical cancer raise concern about antiviral therapy in some cases
8. PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network
9. June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy
10. Filtersfast.com Launches Spazazz Aromatherapy Spa & Bath Crystals
11. Newly Released Continuing Education Courses Provide Physical and Occupational Therapy Professionals With Opportunities To Expand Skill Sets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... 2017 , ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique ... a proprietary technique that he calls the AuraLyft Facelift. The AuraLyft does ... patients can expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique ...
(Date:6/23/2017)... Beach, FL (PRWEB) , ... June 23, 2017 , ... ... in Pinecrest, Florida. This is MD Now’s 28th facility overall and marks the urgent ... Dixie Highway, located one mile North of The Falls shopping mall. The new clinic ...
(Date:6/23/2017)... Francisco, CA (PRWEB) , ... June 23, 2017 , ... ... on 26th June, 2017 from 9 am to 3 pm to present to graduate ... The program is an original curriculum project led by The Health Improvement Service ...
(Date:6/23/2017)... ... 2017 , ... Radabaugh & Associates, a locally owned firm ... in North Central West Virginia, is embarking on a cooperative charity drive with ... the region. , The Stepping Stones organization offers a series of personal development ...
(Date:6/22/2017)... ... June 22, 2017 , ... United Benefit Advisors (UBA), the ... Company as its newest Partner Firm. Headquartered in Coconut Creek, Florida, Whipple & ... tailoring optimized benefit packages that strengthen the relationship between employer and employee. , ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... and INDIANAPOLIS , June 9, 2017 ... with diabetes. In a further effort to help spread ... by this condition, the International Diabetes Federation (IDF) and ... have come together for the second phase of the ... programme (BRIDGES 2), reaffirming their commitment to helping people ...
(Date:6/7/2017)... June 7, 2017  Novavax, Inc., (Nasdaq: NVAX ... Phase 2 trials of its RSV F protein recombinant nanoparticle ... age have been published in the journal Vaccine ... shared in prior scientific conferences). The Company previously announced ... Novavax is developing the RSV F Vaccine with the goal ...
(Date:6/2/2017)... Mass. , June 2, 2017  NxStage Medical, ... renal care, today announced new findings demonstrating positive biochemical ... ® System One™. The data will be presented ... in Madrid, Spain . ... to Improve Home Dialysis Network in Europe ...
Breaking Medicine Technology: